CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net income	$ 185,959	$ 128,291	$ 59,926
Adjustments to reconcile net income to net cash provided by operating activities:
Inventory step-up charges	0	2,130	734
Depreciation and amortization	50,985	38,447	27,067
Amortization of debt discount and issuance costs	1,815	11,530	10,970
Stock-based compensation expense	27,316	27,500	17,007
Contingent consideration expense	(28,729)	5,865	0
Deferred income taxes, net	(1,352)	6,517	(3,992)
Other	(100)	864	267
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(3,596)	(46,523)	(20,892)
Inventories	(57,204)	(89,781)	(29,994)
Prepaid expenses and other assets	2,396	(10,192)	(4,870)
Operating lease right of use assets	(24,549)	(4,315)	3,583
Other assets	(231)	430	175
Accounts payable	(8,197)	19,523	2,462
Accrued expenses	(2,019)	23,196	1,037
Operating lease liability	28,623	6,958	(1,964)
Long-term liabilities	966	(1,424)	1,109
Total cash provided by operating activities	172,083	119,016	62,625
Cash flows from investing activities:
Purchase of marketable securities held to maturity	(100,000)	0	0
Additions to capitalized software costs	(3,512)	(4,187)	(3,889)
Acquisitions, net of cash acquired	0	(149,893)	(175,041)
Purchases of property, plant and equipment	(84,834)	(67,089)	(22,455)
Purchase of intellectual property	(45,000)	0	0
Other investing activities	110	0	0
Total cash used in investing activities	(233,236)	(221,169)	(201,385)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	0	0	297,775
Proceeds from exercise of stock options	3,707	3,879	8,151
Repayment of Convertible Senior Notes	(26)	(21)	0
Payment of tax withholding obligation on vesting of restricted stock	(17,018)	(2,897)	(10)
Total cash (used in) provided by financing activities	(13,337)	961	305,916
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(5,866)	(12,286)	12,729
Net (decrease) increase in cash, cash equivalents and restricted cash	(80,356)	(113,478)	179,885
Cash, cash equivalents and restricted cash, beginning of period	603,814	717,292	537,407
Cash and cash equivalents, end of period	523,458	603,814	717,292
Supplemental disclosure of cash flow information:
Income taxes paid	34,365	16,515	10,279
Interest paid	1,033	1,066	1,066
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	29,126	85,312	3,349
ARTeSYN Biosolutions Holdings Ireland Limited
Supplemental disclosure of non-cash investing and financing activities:
Fair value of earnouts related to acquisition	0	0	69,422
Avitide, Inc.
Adjustments to reconcile net income to net cash provided by operating activities:
Contingent consideration expense	28,700	5,900
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition	0	82,968	0
Fair value of earnouts related to acquisition	$ 0	$ 94,238	$ 0